Top

Reactions Weekly

Published in:

01-02-2024 | Ependymoma | Case report

Erdafitinib

Compassionate-use, no therapeutic response and off-label use

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Stepien N, et al. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients. Pediatric Blood and Cancer 71: No. 3, Mar 2024. Available from: URL: https://dx.doi.org/10.1002/pbc.30836

Title: Erdafitinib
Compassionate-use, no therapeutic response and off-label use
Publication date: 01-02-2024
Publisher: Springer International Publishing
Keywords: Ependymoma
Ependymoma
Ependymoma
Diarrhea
Diarrhea
Leg Pain
Leg Pain
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-53554-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Erdafitinib

Compassionate-use, no therapeutic response and off-label use

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Atorvastatin

Multiple drugs

Meropenem/Terbinafine

Diazepam/Melatonin/Sultiame

Obinutuzumab

Pantoprazole